Nice breakdown. One critical mechanism of immune evasion that deserves a spot in this playbook is the shedding of TNF RECEPTORS (sTNFRs). Many aggressive tumors utilize enzymes to 'shed' their surface receptors into the serum. This creates a systemic 'sink' that prevents the immune system from inducing apoptosis. The soluble, shedded receptors act as DECOYS, neutralizing TNF-α before it reaches the tumor. Once these decoys are removed, the body's own TNF-α is freed to induce RAPID tumor lysis and re-activate CD8+ T-cell infiltration. It’s a powerful way to turn a tumor’s own defense mechanism against itself. Addressing this via ultrapheresis—physically removing these shed blocking factors—has been shown by Letz and others to be an effective adjunct to restore the body's innate ability to powerfully induce tumor lysis. It’s a mechanical solution to a biochemical shield and fits the model of pregnancy in most animals (and all mammals). Founational citation on “subtractive immunotherapeutic apheresis: https://immunicom.com/news/aacr-annual-meeting-2023/
During medical school (1987) I did a 3-week oncology elective with Dr. Rigdon Lentz who pioneered the therapy (started on dogs with mammary adenocarcinoma). I saw amazing results on human cancer patients at Palm Springs hospital (phase 3 trials). Eg, complete resolution of metastatic prostate cancers, and more. I assisted with cleaning the ultrapharesis ‘filters’ (this was before the column technology, which is more selective). The challenge is not getting a tumoricidal response. It’s controlling it (pulling in on the reins) so as to avoid tumor necrosis syndrome. Dr. Lentz may still be alive. I know that about 20 years ago the FDA hampered his research by accusing him of “improper record keeping.” He then moved operations to Germany. I emailed him recently, but no response. If still alive, he’s probably in his late 90s. Bottom line: this is a remarkable hemo-procedural cancer therapy that has an exquisite biological model (gestation and onset of labor) and threatens the Chemo Industrial Complex in a big way.
Diagnosed SLE here. Currently going through ovarian cancer treatment. Would it be fair to say that there should be more collaboration between rheumatologists and oncologists at the start of Lupus diagnoses to determine if cancer is involved should be more common practice? None of my rheumatologists looked at cancer as a factor, although I had markers in my blood that indicated there could be an issue. My cancer wasn’t discovered until my obgyn paid attention to those numbers and other symptoms I reported.
Thank You, Dr. Marik. I am reminded of tactics, strategy and logistics in human warfare, something I have been watching a lot in recent years, somehow.
To prevent the setting up of a tumor microenvironment seems critical, and our bodies usually do this routinely…
I cannot but think of the interruptions to this routine protection through identification and destruction of the abnormal, which is so often brought about by the (m)mRNA COVID gene-therapy vaccine-products.
I was eating a bowl of kale I had just picked from my garden and cooked as I read this, which seemed somehow appropriate to the context.
There is always this debate over the danger of using HBOT and EWOT which are angiogenesis promoting treatments as it relates to tumor promoting angiogenesis and growth with metastasis as you have described in this excellent article. Where do you stand on using Hyperbaric O2 Rx and Exercise With O2 Rx in patients with established cancer Dx such as breast, prostate, etc. Thanks.
Nice breakdown. One critical mechanism of immune evasion that deserves a spot in this playbook is the shedding of TNF RECEPTORS (sTNFRs). Many aggressive tumors utilize enzymes to 'shed' their surface receptors into the serum. This creates a systemic 'sink' that prevents the immune system from inducing apoptosis. The soluble, shedded receptors act as DECOYS, neutralizing TNF-α before it reaches the tumor. Once these decoys are removed, the body's own TNF-α is freed to induce RAPID tumor lysis and re-activate CD8+ T-cell infiltration. It’s a powerful way to turn a tumor’s own defense mechanism against itself. Addressing this via ultrapheresis—physically removing these shed blocking factors—has been shown by Letz and others to be an effective adjunct to restore the body's innate ability to powerfully induce tumor lysis. It’s a mechanical solution to a biochemical shield and fits the model of pregnancy in most animals (and all mammals). Founational citation on “subtractive immunotherapeutic apheresis: https://immunicom.com/news/aacr-annual-meeting-2023/
Thanks. You can contact me at pmarik@protonmail.com
Thanks. I will look at this in more detail.
During medical school (1987) I did a 3-week oncology elective with Dr. Rigdon Lentz who pioneered the therapy (started on dogs with mammary adenocarcinoma). I saw amazing results on human cancer patients at Palm Springs hospital (phase 3 trials). Eg, complete resolution of metastatic prostate cancers, and more. I assisted with cleaning the ultrapharesis ‘filters’ (this was before the column technology, which is more selective). The challenge is not getting a tumoricidal response. It’s controlling it (pulling in on the reins) so as to avoid tumor necrosis syndrome. Dr. Lentz may still be alive. I know that about 20 years ago the FDA hampered his research by accusing him of “improper record keeping.” He then moved operations to Germany. I emailed him recently, but no response. If still alive, he’s probably in his late 90s. Bottom line: this is a remarkable hemo-procedural cancer therapy that has an exquisite biological model (gestation and onset of labor) and threatens the Chemo Industrial Complex in a big way.
Thanks for this. Very interesting. I updated the post.
Would regular use proteolytic enzymes trigger shedding of TNF Receptors?
Like military jets releasing flares to attract heat seeking air-defense missiles and distract them from the real target…
Good question. I am nor sure.
Diagnosed SLE here. Currently going through ovarian cancer treatment. Would it be fair to say that there should be more collaboration between rheumatologists and oncologists at the start of Lupus diagnoses to determine if cancer is involved should be more common practice? None of my rheumatologists looked at cancer as a factor, although I had markers in my blood that indicated there could be an issue. My cancer wasn’t discovered until my obgyn paid attention to those numbers and other symptoms I reported.
Yes, good question
Another great post, Dr Marik. Thank you very much for sharing!
Thank You, Dr. Marik. I am reminded of tactics, strategy and logistics in human warfare, something I have been watching a lot in recent years, somehow.
To prevent the setting up of a tumor microenvironment seems critical, and our bodies usually do this routinely…
I cannot but think of the interruptions to this routine protection through identification and destruction of the abnormal, which is so often brought about by the (m)mRNA COVID gene-therapy vaccine-products.
I was eating a bowl of kale I had just picked from my garden and cooked as I read this, which seemed somehow appropriate to the context.
Thanks I agree. I have upcoming posts on this topic.
What effect does the microclots,caused by “spikeopathy “ have on creating low oxygen in many areas?
Baie Goed. en ankename kennis
Spike protein is the enemy of cancer… it drives cancer. I have a forthcoming substack on this topic.
Hello Paul,
There is always this debate over the danger of using HBOT and EWOT which are angiogenesis promoting treatments as it relates to tumor promoting angiogenesis and growth with metastasis as you have described in this excellent article. Where do you stand on using Hyperbaric O2 Rx and Exercise With O2 Rx in patients with established cancer Dx such as breast, prostate, etc. Thanks.
Mich: I address HBOT in one of the later posts. I do not think it has any role except perhaps to heal flaps in H&N surgery.